Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field.
Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases.
We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.
Our most advanced product
DAV132 is a microbiota protective therapy developed to prevent antibiotic-induced dysbiosis. It has already undergone multiple clinical trials and is currently studied in one multi-centric phase 2 study in Europe. It has been developed using in-house expertise on antibiotics, gut microbiota and drug delivery technologies.